About the Authors
- Kari Hemminki
-
Roles Conceptualization, Formal analysis, Project administration
* E-mail: K.Hemminki@dkfz.de
Affiliations Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Asta Försti
-
Roles Investigation, Validation
Affiliations Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany, Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
- Akseli Hemminki
-
Roles Investigation, Validation
Affiliations Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
- Börje Ljungberg
-
Roles Investigation, Validation
Affiliation Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
- Otto Hemminki
-
Roles Conceptualization, Formal analysis, Supervision
Affiliations Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, Division of Urologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, Ontario, Canada
Competing Interests
The authors have read the journal’s policy and have the following competing interests: AH is shareholder in Targovax ASA. AH is also employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.